Clinical Trial Update: Kisspeptin Administration Subcutaneously to Patients With IHH [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is evaluating subcutaneous kisspeptin administration in patients with hypogonadotropic hypogonadism and is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypogonadotropic Hypogonadism

Drugs mentioned

• Kisspeptin (Kisspeptin)

Snippet

Sponsor: Stephanie B. Seminara, MD | Conditions: Hypogonadotropic Hypogonadism | Phase 2 | Status: RECRUITING